Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Imatinib mesylate treatment markedly reduces the burden of leukemia cells in chronic myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on discontinuing treatment. We have previously shown that residual BCR-ABL+ progenitors can be detected in CML patients within the fi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2011-11, Vol.118 (20), p.5565-5572
Hauptverfasser:	Chu, Su, McDonald, Tinisha, Lin, Allen, Chakraborty, Sujata, Huang, Qin, Snyder, David S., Bhatia, Ravi
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Benzamides Biological and medical sciences Bone Marrow - pathology Fusion Proteins, bcr-abl - genetics Hematologic and hematopoietic diseases Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Mice Mice, Inbred NOD Mice, Knockout Mice, SCID Myeloid Neoplasia Neoplasm Transplantation Neoplasm, Residual - pathology Neoplastic Stem Cells - pathology Piperazines - administration & dosage Piperazines - adverse effects Pyrimidines - administration & dosage Pyrimidines - adverse effects Remission Induction Substance Withdrawal Syndrome - pathology Time Factors Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!